nigel.stanger / Digital_Repository
Transfer to URL with SHA Find file
Newer
Older
Digital_Repository / Misc / Mass downloads / UTas / 2357.html
Nigel Stanger on 7 May 2013 65 KB - Imported Misc directory.
Raw Blame History 
  1. <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  2. "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
  3. <html>
  4.   <head>
  5.     <title>UTas ePrints - Tissue factor pathway inhibitor: Regulator of the tissue factor pathway of coagulation and a future antithrombotic agent?</title>
  6.     <script type="text/javascript" src="http://eprints.utas.edu.au/javascript/auto.js"><!-- padder --></script>
  7.     <style type="text/css" media="screen">@import url(http://eprints.utas.edu.au/style/auto.css);</style>
  8.     <style type="text/css" media="print">@import url(http://eprints.utas.edu.au/style/print.css);</style>
  9.     <link rel="icon" href="/images/eprints/favicon.ico" type="image/x-icon" />
  10.     <link rel="shortcut icon" href="/images/eprints/favicon.ico" type="image/x-icon" />
  11.     <link rel="Top" href="http://eprints.utas.edu.au/" />
  12.     <link rel="Search" href="http://eprints.utas.edu.au/cgi/search" />
  13.     <meta content="Adams, M.J." name="eprints.creators_name" />
  14. <meta content="Oostryck, R." name="eprints.creators_name" />
  15. <meta content="Murray.Adams@utas.edu.au" name="eprints.creators_id" />
  16. <meta content="" name="eprints.creators_id" />
  17. <meta content="article" name="eprints.type" />
  18. <meta content="2007-11-02 00:22:21" name="eprints.datestamp" />
  19. <meta content="2008-01-08 15:30:00" name="eprints.lastmod" />
  20. <meta content="show" name="eprints.metadata_visibility" />
  21. <meta content="Tissue factor pathway inhibitor: Regulator of the tissue factor pathway of coagulation and a future antithrombotic agent?" name="eprints.title" />
  22. <meta content="pub" name="eprints.ispublished" />
  23. <meta content="320000" name="eprints.subjects" />
  24. <meta content="restricted" name="eprints.full_text_status" />
  25. <meta content="Antithrombotic agent; Coagulation; Thrombosis; Tissue factor; Tissue factor pathway inhibitor
  26.  
  27.  
  28.  
  29. " name="eprints.keywords" />
  30. <meta content="Tissue factor pathway inhibitor (TFPI) is a recently 'rediscovered' inhibitor of tissue factor mediated coagulation that has a central role in the modern hypothesis of coagulation. The regulatory role of this inhibitor has redefined the classical extrinsic and intrinsic pathways of coagulation and helps to explain why haemophiliacs bleed. Comprehensive investigations have been performed during the last 15 years to elucidate the structure, distribution, function and physiological characteristics of TFPI. More recent work has focused on the therapeutic potential of TFPI as an antithrombotic agent. Augmentation of TFPI levels may provide treatment for thrombotic disorders such as disseminated intravascular coagulation and deep vein thrombosis. Full length and truncated forms of TFPI molecules are also being considered as antithrombotic agents. These have been used in a number of animal models with initial results demonstrating the alleviation of thrombotic tendencies. Trials are currently ongoing." name="eprints.abstract" />
  31. <meta content="2000" name="eprints.date" />
  32. <meta content="published" name="eprints.date_type" />
  33. <meta content="Australian Journal of Medical Science" name="eprints.publication" />
  34. <meta content="21" name="eprints.volume" />
  35. <meta content="1" name="eprints.number" />
  36. <meta content="2-9" name="eprints.pagerange" />
  37. <meta content="TRUE" name="eprints.refereed" />
  38. <meta content="1038-1643" name="eprints.issn" />
  39. <meta content="http://www.aims.org.au/c/" name="eprints.official_url" />
  40. <meta content="1.Davie, E.W., Ratnoff, O.D.
  41. Waterfall sequence for intrinsic blood clotting
  42. (1964) Science, 145, pp. 1310-1312. Cited 171 times.
  43. 2.    MacFarlane, R.G.
  44. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier
  45. (1964) Nature, 202, pp. 498-499. Cited 162 times.
  46. 3.    Sanders, N.L., Bajaj, S.P., Zivelin, A., Rapaport, S.I.
  47. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component
  48. (1985) Blood, 66 (1), pp. 204-212. Cited 37 times.
  49. 4Loeb, L., Fleisher, M.S., Tuttle, L.
  50. The interaction between blood serum and tissue extract in the coagulation of blood. i the combined action of serum and tissue extract on fluoride, hirudin and peptone plasma, and the effect of heating on serum
  51. (1922) J Biol Chem, 51, pp. 461-484. Cited 2 times.
  52. 5.    Hjort, P.F.
  53. Intermediate reactions in the coagulation of blood with tissue thromboplastin
  54. (1957) Scand J Clin Lab Invest, 9, pp. 1-182. Cited 34 times.
  55. 6.    Marlar, R.A., Kleiss, A.J., Griffin, J.H.
  56. An alternative extrinsic pathway of human blood coagulation
  57. (1982) Blood, 60 (6), pp. 1353-1358. Cited 24 times.
  58. 7.    Girard, T.J., Eddy, R., Wesselschmidt, R.L., MacPhail, L.A., Likert, K.M., Byers, M.G., Shows, T.B., (...), Broze Jr., G.J.
  59. Structure of the human lipoprotein-associated coagulation inhibitor gene: Intro/exon gene organization and localization of the gene to chromosome 2
  60. (1991) Journal of Biological Chemistry, 266 (8), pp. 5036-5041. Cited 29 times.
  61. 8.    Wun, T.-C., Kretzmer, K.K., Girard, T.J., Miletich, J.P., Broze Jr., G.J.
  62. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
  63. (1988) Journal of Biological Chemistry, 263 (13), pp. 6001-6004. Cited 146 times.
  64. 9.    Broze Jr., G.J., Girard, T.J., Novotny, W.F.
  65. Regulation of coagulation by a multivalent Kunitz-type inhibitor
  66. (1990) Biochemistry, 29 (33), pp. 7539-7546. Cited 180 times.
  67. 10.    Lindahl, A.K., Sandset, P.M., Abildgaard, U.
  68. The present status of tissue factor pathway inhibitor
  69. (1992) Blood Coagulation and Fibrinolysis, 3 (4), pp. 439-449. Cited 84 times.
  70. 11.    Broze Jr., G.J.
  71. Why do hemophiliacs bleed?
  72. (1992) Hospital Practice, 27 (3), pp. 71-74+79. Cited 8 times.
  73. 12.    Sandset, P.M., Abildgaard, U., Pettersen, M.
  74. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions
  75. (1987) Thrombosis Research, 47 (4), pp. 389-400. Cited 55 times 
  76. 13.    Novotny, W.F., Brown, S.G., Miletich, J.P., Rader, D.J., Broze Jr., G.J.
  77. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
  78. (1991) Blood, 78 (2), pp. 387-393. Cited 141 times.
  79. 14.    Bauer, K.A., Kass, B.L., Ten Cate, H., Bednarek, M.A., Hawiger, J.J., Rosenberg, R.D.
  80. Detection of factor X activation in humans
  81. (1989) Blood, 74 (6), pp. 2007-2015. Cited 57 times.
  82. 15.    Carson, S.D.
  83. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor
  84. (1981) FEBS Letters, 132 (1), pp. 37-40. Cited 11 times.
  85. doi: 10.1016/0014-5793(81)80422-X
  86. 16.    Hubbard, A.R., Jennings, C.A.
  87. Inhibition of the tissue factor-Factor VII complex: Involvement of Factor Xa and lipoproteins
  88. (1987) Thrombosis Research, 46 (4), pp. 527-537. Cited 28 times.
  89. 17.    Novotny, W.F., Girard, T.J., Miletich, J.P., Broze Jr., G.J.
  90. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor
  91. (1988) Blood, 72 (6), pp. 2020-2025. Cited 96 times.
  92. 18.    Rao, L.V.M., Rapaport, S.I.
  93. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation
  94. (1987) Blood, 69 (2), pp. 645-651. Cited 67 times.
  95. 19.    Warn-Cramer, B.J., Rao, L.V.M., Maki, S.L., Rapaport, S.I.
  96. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition
  97. (1988) Thrombosis and Haemostasis, 60 (3), pp. 453-456. Cited 43 times.
  98. 20.    Broze Jr., G.J., Warren, L.A., Novotny, W.F., Higuchi, D.A., Girard, J.J., Miletich, J.P.
  99. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
  100. (1988) Blood, 71 (2), pp. 335-343. Cited 204 times.
  101. 21.    Warr, T.A., Warn-Cramer, B.J., Rao, L.V.M., Rapaport, S.I.
  102. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables
  103. (1989) Blood, 74 (1), pp. 201-206. Cited 17 times.
  104. 22.    Rapaport, S.I.
  105. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism
  106. (1989) Blood, 73 (2), pp. 359-365. Cited 52 times.
  107. 23.    Sandset, P.M., Larsen, M.L., Abildgaard, U., Lindahl, A.K., Odegaard, O.R.
  108. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol.
  109. (1991) Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis, 2 (3), pp. 425-433. Cited 71 times.
  110. 24.    Novotny, W.F., Girard, T.J., Miletich, J.P., Broze Jr., G.J.
  111. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma
  112. (1989) Journal of Biological Chemistry, 264 (31), pp. 18832-18837. Cited 89 times.
  113. 25.    Reverdiau-Moalic, P., Delahousse, B., Body, G., Bardos, P., Leroy, J., Gruel, Y.
  114. Evolution of blood coagulation activators and inhibitors in the healthy human fetus
  115. (1996) Blood, 88 (3), pp. 900-906. Cited 75 times.
  116. 26.    Sandset, P.M., Roise, O., Aasen, A.O., Abildgaard, U.
  117. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases
  118. (1989) Haemostasis, 19 (4), pp. 189-195. Cited 25 times.
  119. 27.    Sandset, P.M., Lund, H., Norseth, J., Abildgaard, U., Ose, L.
  120. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
  121. (1991) Arteriosclerosis and Thrombosis, 11 (1), pp. 138-145. Cited 61 times.
  122. 28.    Moor, E., Hamsten, A., Karpe, F., Bavenholm, P., Blomback, M., Silveira, A.
  123. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age
  124. (1994) Thrombosis and Haemostasis, 71 (6), pp. 707-712. Cited 31 times. 
  125. 29.    Kamikura, Y., Wada, H., Yamada, A., Shimura, M., Hiyoyama, K., Shiku, H., Tanigawa, M., (...), Kato, H.
  126. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
  127. (1997) American Journal of Hematology, 55 (4), pp. 183-187. Cited 31 times.
  128. doi: 10.1002/(SICI)1096-8652(199707)55:4<183::AID-AJH3>3.0.CO;2-O 
  129. 30.    Berrettini, M., Malaspina, M., Parise, P., Lucarelli, G., Kisiel, W., Nenci, G.G.
  130. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum
  131. (1995) American Journal of Clinical Pathology, 103 (4), pp. 391-395. Cited 6 times. 
  132. 31.    Leurs, P.B., Van Oerle, R., Hamulyak, K., Wolffenbuttel, B.H.R.
  133. Tissue factor pathway inhibitor activity in patients with IDDM
  134. (1995) Diabetes, 44 (1), pp. 80-84. Cited 28 times.
  135. 32.    Leurs, P.B., Van Oerle, R., Wolffenbuttel, B.H.R., Hamulyak, K.
  136. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus
  137. (1997) Thrombosis and Haemostasis, 77 (3), pp. 472-476. Cited 26 times.
  138. 33.    Sandset, P.M., Sirnes, P.A., Abildgaard, U.
  139. Factor VII and extrinsic pathway inhibitor in acute coronary disease
  140. (1989) British Journal of Haematology, 72 (3), pp. 391-396. Cited 34 times.
  141. 34.    Bajaj, M.S., Rana, S.V., Wysolmerski, R.B., Bajaj, S.P.
  142. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease.
  143. (1987) Journal of Clinical Investigation, 79 (6), pp. 1874-1878. Cited 32 times.
  144. 35.    Warr, T.A., Mohan Rao, L.V., Rapaport, S.I.
  145. Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease
  146. (1989) Blood, 74 (3), pp. 994-998. Cited 21 times.
  147.   36.    Lorena, M., Perolini, S., Casazza, F., Milani, M., Cimminiello, C.
  148. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction
  149. (1997) Thrombosis Research, 87 (4), pp. 397-403. Cited 15 times.
  150. doi: 10.1016/S0049-3848(97)00143-6
  151. 37.    Öksüzoǧlu, G., Simsek, H., Haznedaroǧlu, I.C., Kirazli, Ş.
  152. Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis
  153. (1997) American Journal of Gastroenterology, 92 (2), pp. 303-306. Cited 16 times.
  154. 38.    Kobayashi, M., Wada, H., Wakita, Y., Shimura, M., Nakase, T., Hiyoyama, K., Nagaya, S., (...), Shiku, H.
  155. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura
  156. (1995) Thrombosis and Haemostasis, 73 (1), pp. 10-14. Cited 37 times.
  157. 39.    Goodwin, C.A., Melissari, E., Kakkar, V.V., Scully, M.F.
  158. Plasma levels of tissue factor pathway inhibitor in thrombophilic patients
  159. (1993) Thrombosis Research, 72 (4), pp. 363-366. Cited 8 times.
  160. doi: 10.1016/0049-3848(93)90147-G
  161. 40.    Llobet, D., Falkon, L., Mateo, J., Vallve, C., Martinez, E., Fontcuberta, J., Borrell, M.
  162. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia.
  163. (1995) Thrombosis Research, 80 (5), pp. 413-418. Cited 15 times.
  164. doi: 10.1016/0049-3848(95)00193-U
  165. 41.    Lindahl, A.K., Jacobsen, P.B., Sandset, P.M., Abildgaard, U.
  166. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients.
  167. (1991) Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis, 2 (6), pp. 713-721. Cited 59 times.
  168. 42.    Wildgoose, P.S., Valentin, S., Nordfang, O.
  169. Evidence that the C-terminus of tissue factor pathwway inhibitor (TFPI) is essential for its interaction with lipoproteins
  170. (1991) Thromb Haemost, 65, p. 768. Cited 2 times.
  171. 43.    Valentin, S., Nordfang, O., Bregengard, C., Wildgoose, P.
  172. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins
  173. (1993) Blood Coagulation and Fibrinolysis, 4 (5), pp. 713-720. Cited 43 times.
  174. 44.    Sandset, P.M., Abildgaard, U., Larsen, M.L.
  175. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
  176. (1988) Thrombosis Research, 50 (6), pp. 803-813. Cited 223 times.
  177. 45.    Hoppensteadt, D.A., Walenga, J.M., Fasanella, A., Jeske, W., Farced, J.
  178. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin
  179. (1995) Thrombosis Research, 77 (2), pp. 175-185. Cited 46 times.
  180. doi: 10.1016/0049-3848(95)91623-S
  181. 46.    Lindahl, A.K., Sandset, P.M., Abildgaard, U.
  182. Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction
  183. (1990) Haemostasis, 20 (5), pp. 253-262. Cited 20 times.
  184. 47.    Ostergaard, P., Nordfang, O., Petersen, L.C., Valentin, S., Kristensen, H.
  185. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations
  186. (1993) Haemostasis, 23 (SUPPL. 1), pp. 107-111. Cited 15 times.
  187. 48.    Hoppensteadt, D.A., Fasanella, A., Fareed, J.
  188. Effect of protamine on heparin releasable TFPI antigen levels in normal volunteers
  189. (1995) Thrombosis Research, 79 (3), pp. 325-330. Cited 2 times.
  190. doi: 10.1016/0049-3848(95)00119-C
  191. 49.    Bara, L., Bloch, M.F., Zitoun, D., Samama, M., Collignon, F., Frydman, A., Uzan, A., (...), Bouthier, J.
  192. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor
  193. (1993) Thrombosis Research, 69 (5), pp. 443-452. Cited 46 times.
  194. doi: 10.1016/0049-3848(93)90233-E
  195. 50.    Ariens, R.A.S., Faioni, E.M., Mannucci, P.M.
  196. Repeated release of the tissue factor pathway inhibitor [3]
  197. (1994) Thrombosis and Haemostasis, 72 (2), pp. 327-328. Cited 11 times.
  198. 51.    Abildgaard, U.
  199. Heparin/low molecular weight heparin and tissue factor pathway inhibitor
  200. (1993) Haemostasis, 23 (SUPPL. 1), pp. 103-106. Cited 37 times.
  201. 52.    Hansen, J.-B., Sandset, P.M., Huseby, K.R., Huseby, N.-E., Bendz, B., Østergaard, P., Nordøy, A.
  202. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action
  203. (1998) British Journal of Haematology, 101 (4), pp. 638-646. Cited 38 times.
  204. doi: 10.1046/j.1365-2141.1998.00770.x
  205. 53.    Kaiser, B., Hoppensteadt, D.A., Jeske, W., Wun, T.C., Fareed, J.
  206. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitromodulatory action of glycosaminoglycans
  207. (1994) Thrombosis Research, 75 (6), pp. 609-616. Cited 16 times.
  208. doi: 10.1016/0049-3848(94)90173-2
  209. 54.    Wun, T.-C.
  210. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides
  211. (1992) Blood, 79 (2), pp. 430-438. Cited 26 times.
  212. 55.    Wesselschmidt, R., Likert, K., Girard, T., Wun, T.-C., Broze Jr., G.J.
  213. Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa
  214. (1992) Blood, 79 (8), pp. 2004-2010. Cited 79 times.
  215. 56.    Kijowski, R., Hoppensteadt, D., Walenga, J., Borris, L., Lassen, M.R., Fareed, J.
  216. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin
  217. (1994) Thrombosis Research, 74 (1), pp. 53-64. Cited 13 times.
  218. doi: 10.1016/0049-3848(94)90035-3
  219.  
  220. 57.    Erhardtsen, E., Madsen, M.T., Ezban, M., Hedner, U., Diness, V., Glazer, S., Nordfang, O.
  221. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced hemophilia A
  222. (1993) Thromb Haemost, 69, p. 556. Cited 5 times.
  223.  
  224. 58.    Holst, J., Lindblad, B., Bergqvist, D., Nordfang, O., Ostergaard, P.B., Petersen, J.G.L., Nielsen, G., (...), Hedner, U.
  225. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI) in experimental venous thrombosis: A comparison with low molecular weight heparin
  226. (1994) Thrombosis and Haemostasis, 71 (2), pp. 214-219. Cited 36 times.
  227. 59.    Hamamoto, T., Yamamoto, M., Nordfang, O., Petersen, J.G.L., Foster, D.C., Kisiel, W.
  228. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces
  229. (1993) Journal of Biological Chemistry, 268 (12), pp. 8704-8710. Cited 41 times.
  230. 60.    Holst, J., Lindblad, B., Wedeberg, E., Bergqvist, D., Nordfang, O., Ostergaard, P.B., Hedner, U.
  231. Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
  232. (1993) Thrombosis Research, 72 (5), pp. 467-470. Cited 11 times.
  233. doi: 10.1016/0049-3848(93)90248-M
  234. 61.    Girard, T.J., MacPhail, L.A., Likert, K.M., Novotny, W.F., Miletich, J.P., Broze Jr., G.J.
  235. Inhibition of a factor VIIa-tissue factor coagulation activity by a hybrid protein
  236. (1990) Science, 248 (4961), pp. 1421-1424. Cited 38 times.
  237. 62.    Day, K.C., Welsch, D.J.
  238. Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor XA
  239. (1992) Thrombosis Research, 68 (4-5), pp. 369-381. Cited 6 times.
  240. doi: 10.1016/0049-3848(92)90095-R
  241. 63.    Eisenberg, P.R., Siegel, J.E., Abendschein, D.R., Miletich, J.P.
  242. Importance of factor Xa in determining the procoagulant activity of whole- blood clots
  243. (1993) Journal of Clinical Investigation, 91 (5), pp. 1877-1883. Cited 108 times.
  244. 64.    Lindhout, T., Franssen, J., Willems, G.
  245. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor
  246. (1995) Thrombosis and Haemostasis, 74 (3), pp. 910-915. Cited 40 times.
  247. 65.    Broze Jr., G.J.
  248. Tissue factor pathway inhibitor
  249. (1995) Thrombosis and Haemostasis, 74 (1), pp. 90-93. Cited 206 times.
  250. 66.    Enjoyji, K., Miyata, T., Kamikubo, Y., Kato, J.
  251. Effect of heparin on the inhibition of FXa by tissue factor pathway inhibitor: A segment, Gly212- Phe 243, of the third kunitz domain is a heparin binding site
  252. (1995) Biochemistry, 34, pp. 5727-5735.
  253. 67.    Bajaj, M.S., Bajaj, S.P.
  254. Tissue factor pathway inhibitor: Potential therapeutic applications
  255. (1997) Thrombosis and Haemostasis, 78 (1), pp. 471-477. Cited 94 times.
  256. 68.    Kamikubo, Y.-I., Hamuro, T., Matsuda, J.-I., Kamei, S., Jyu-Ri, K., Miyamoto, S., Funatsu, A., (...), Kato, H.
  257. The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (H-RTFPI) in rabbits: A complex formation of H- RTFPI with factor Xa promotes a clearance rate of H-RTFPI
  258. (1996) Thrombosis Research, 83 (2), pp. 161-173. Cited 9 times.
  259. doi: 10.1016/0049-3848(96)00117-X
  260. 69.    Holst, J., Lindblad, B., Westerlund, G., Bregengaard, C., Ezban, M., ØStergaard, P.B., Nordfang, O., (...), Hedner, U.
  261. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor
  262. (1996) Thrombosis Research, 81 (4), pp. 461-470. Cited 6 times.
  263. doi: 10.1016/0049-3848(96)00018-7
  264.  70.    Day, K.C., Hoffman, L.C., Palmier, M.O., Kretzmer, K.K., Huang, M.D., Pyla, E.Y., Spokas, E., (...), Wun, T.-C.
  265. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit
  266. (1990) Blood, 76 (8), pp. 1538-1545. Cited 40 times.
  267. 71.    Bregengard, C., Nordfang, O., Wildgoose, P., Svendsen, O., Hedner, U., Diness, V.
  268. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits
  269. (1993) Blood Coagulation and Fibrinolysis, 4 (5), pp. 699-706. Cited 49 times.
  270. 72.    Camerota, A.J., Creasey, A.A., Patla, V., Larkin, V.A., Fink, M.P.
  271. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
  272. (1998) Journal of Infectious Diseases, 177 (3), pp. 668-676. Cited 63 times.
  273.  73.    Girard, T.J.
  274. Tissue factor pathway inhibitor
  275. (1997) Novel Therapeutic Agents in Thrombosis and Thrombolysis, pp. 225-260. Cited 8 times.
  276. Sasahara A, Loscalzo J, eds. New York: Marcel Dekker
  277. Oostryck, R.; School of Biomedical Sciences, Curtin University of Technology, GPO Box U 1987, Perth, WA 6845, Australia; email:r.oostryck@info.curtin.edu.au 
  278. © Copyright 2006 Elsevier B.V., All rights reserved
  279.  
  280.  
  281.  
  282.  
  283. 1.Davie, E.W., Ratnoff, O.D.
  284. Waterfall sequence for intrinsic blood clotting
  285. (1964) Science, 145, pp. 1310-1312. Cited 171 times.
  286. 2.    MacFarlane, R.G.
  287. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier
  288. (1964) Nature, 202, pp. 498-499. Cited 162 times.
  289. 3.    Sanders, N.L., Bajaj, S.P., Zivelin, A., Rapaport, S.I.
  290. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component
  291. (1985) Blood, 66 (1), pp. 204-212. Cited 37 times.
  292. 4Loeb, L., Fleisher, M.S., Tuttle, L.
  293. The interaction between blood serum and tissue extract in the coagulation of blood. i the combined action of serum and tissue extract on fluoride, hirudin and peptone plasma, and the effect of heating on serum
  294. (1922) J Biol Chem, 51, pp. 461-484. Cited 2 times.
  295. 5.    Hjort, P.F.
  296. Intermediate reactions in the coagulation of blood with tissue thromboplastin
  297. (1957) Scand J Clin Lab Invest, 9, pp. 1-182. Cited 34 times.
  298. 6.    Marlar, R.A., Kleiss, A.J., Griffin, J.H.
  299. An alternative extrinsic pathway of human blood coagulation
  300. (1982) Blood, 60 (6), pp. 1353-1358. Cited 24 times.
  301. 7.    Girard, T.J., Eddy, R., Wesselschmidt, R.L., MacPhail, L.A., Likert, K.M., Byers, M.G., Shows, T.B., (...), Broze Jr., G.J.
  302. Structure of the human lipoprotein-associated coagulation inhibitor gene: Intro/exon gene organization and localization of the gene to chromosome 2
  303. (1991) Journal of Biological Chemistry, 266 (8), pp. 5036-5041. Cited 29 times.
  304. 8.    Wun, T.-C., Kretzmer, K.K., Girard, T.J., Miletich, J.P., Broze Jr., G.J.
  305. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
  306. (1988) Journal of Biological Chemistry, 263 (13), pp. 6001-6004. Cited 146 times.
  307. 9.    Broze Jr., G.J., Girard, T.J., Novotny, W.F.
  308. Regulation of coagulation by a multivalent Kunitz-type inhibitor
  309. (1990) Biochemistry, 29 (33), pp. 7539-7546. Cited 180 times.
  310. 10.    Lindahl, A.K., Sandset, P.M., Abildgaard, U.
  311. The present status of tissue factor pathway inhibitor
  312. (1992) Blood Coagulation and Fibrinolysis, 3 (4), pp. 439-449. Cited 84 times.
  313. 11.    Broze Jr., G.J.
  314. Why do hemophiliacs bleed?
  315. (1992) Hospital Practice, 27 (3), pp. 71-74+79. Cited 8 times.
  316. 12.    Sandset, P.M., Abildgaard, U., Pettersen, M.
  317. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions
  318. (1987) Thrombosis Research, 47 (4), pp. 389-400. Cited 55 times 
  319. 13.    Novotny, W.F., Brown, S.G., Miletich, J.P., Rader, D.J., Broze Jr., G.J.
  320. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
  321. (1991) Blood, 78 (2), pp. 387-393. Cited 141 times.
  322. 14.    Bauer, K.A., Kass, B.L., Ten Cate, H., Bednarek, M.A., Hawiger, J.J., Rosenberg, R.D.
  323. Detection of factor X activation in humans
  324. (1989) Blood, 74 (6), pp. 2007-2015. Cited 57 times.
  325. 15.    Carson, S.D.
  326. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor
  327. (1981) FEBS Letters, 132 (1), pp. 37-40. Cited 11 times.
  328. doi: 10.1016/0014-5793(81)80422-X
  329. 16.    Hubbard, A.R., Jennings, C.A.
  330. Inhibition of the tissue factor-Factor VII complex: Involvement of Factor Xa and lipoproteins
  331. (1987) Thrombosis Research, 46 (4), pp. 527-537. Cited 28 times.
  332. 17.    Novotny, W.F., Girard, T.J., Miletich, J.P., Broze Jr., G.J.
  333. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor
  334. (1988) Blood, 72 (6), pp. 2020-2025. Cited 96 times.
  335. 18.    Rao, L.V.M., Rapaport, S.I.
  336. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation
  337. (1987) Blood, 69 (2), pp. 645-651. Cited 67 times.
  338. 19.    Warn-Cramer, B.J., Rao, L.V.M., Maki, S.L., Rapaport, S.I.
  339. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition
  340. (1988) Thrombosis and Haemostasis, 60 (3), pp. 453-456. Cited 43 times.
  341. 20.    Broze Jr., G.J., Warren, L.A., Novotny, W.F., Higuchi, D.A., Girard, J.J., Miletich, J.P.
  342. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
  343. (1988) Blood, 71 (2), pp. 335-343. Cited 204 times.
  344. 21.    Warr, T.A., Warn-Cramer, B.J., Rao, L.V.M., Rapaport, S.I.
  345. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables
  346. (1989) Blood, 74 (1), pp. 201-206. Cited 17 times.
  347. 22.    Rapaport, S.I.
  348. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism
  349. (1989) Blood, 73 (2), pp. 359-365. Cited 52 times.
  350. 23.    Sandset, P.M., Larsen, M.L., Abildgaard, U., Lindahl, A.K., Odegaard, O.R.
  351. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol.
  352. (1991) Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis, 2 (3), pp. 425-433. Cited 71 times.
  353. 24.    Novotny, W.F., Girard, T.J., Miletich, J.P., Broze Jr., G.J.
  354. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma
  355. (1989) Journal of Biological Chemistry, 264 (31), pp. 18832-18837. Cited 89 times.
  356. 25.    Reverdiau-Moalic, P., Delahousse, B., Body, G., Bardos, P., Leroy, J., Gruel, Y.
  357. Evolution of blood coagulation activators and inhibitors in the healthy human fetus
  358. (1996) Blood, 88 (3), pp. 900-906. Cited 75 times.
  359. 26.    Sandset, P.M., Roise, O., Aasen, A.O., Abildgaard, U.
  360. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases
  361. (1989) Haemostasis, 19 (4), pp. 189-195. Cited 25 times.
  362. 27.    Sandset, P.M., Lund, H., Norseth, J., Abildgaard, U., Ose, L.
  363. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
  364. (1991) Arteriosclerosis and Thrombosis, 11 (1), pp. 138-145. Cited 61 times.
  365. 28.    Moor, E., Hamsten, A., Karpe, F., Bavenholm, P., Blomback, M., Silveira, A.
  366. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age
  367. (1994) Thrombosis and Haemostasis, 71 (6), pp. 707-712. Cited 31 times. 
  368. 29.    Kamikura, Y., Wada, H., Yamada, A., Shimura, M., Hiyoyama, K., Shiku, H., Tanigawa, M., (...), Kato, H.
  369. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
  370. (1997) American Journal of Hematology, 55 (4), pp. 183-187. Cited 31 times.
  371. doi: 10.1002/(SICI)1096-8652(199707)55:4<183::AID-AJH3>3.0.CO;2-O 
  372. 30.    Berrettini, M., Malaspina, M., Parise, P., Lucarelli, G., Kisiel, W., Nenci, G.G.
  373. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum
  374. (1995) American Journal of Clinical Pathology, 103 (4), pp. 391-395. Cited 6 times. 
  375. 31.    Leurs, P.B., Van Oerle, R., Hamulyak, K., Wolffenbuttel, B.H.R.
  376. Tissue factor pathway inhibitor activity in patients with IDDM
  377. (1995) Diabetes, 44 (1), pp. 80-84. Cited 28 times.
  378. 32.    Leurs, P.B., Van Oerle, R., Wolffenbuttel, B.H.R., Hamulyak, K.
  379. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus
  380. (1997) Thrombosis and Haemostasis, 77 (3), pp. 472-476. Cited 26 times.
  381. 33.    Sandset, P.M., Sirnes, P.A., Abildgaard, U.
  382. Factor VII and extrinsic pathway inhibitor in acute coronary disease
  383. (1989) British Journal of Haematology, 72 (3), pp. 391-396. Cited 34 times.
  384. 34.    Bajaj, M.S., Rana, S.V., Wysolmerski, R.B., Bajaj, S.P.
  385. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease.
  386. (1987) Journal of Clinical Investigation, 79 (6), pp. 1874-1878. Cited 32 times.
  387. 35.    Warr, T.A., Mohan Rao, L.V., Rapaport, S.I.
  388. Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease
  389. (1989) Blood, 74 (3), pp. 994-998. Cited 21 times.
  390.   36.    Lorena, M., Perolini, S., Casazza, F., Milani, M., Cimminiello, C.
  391. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction
  392. (1997) Thrombosis Research, 87 (4), pp. 397-403. Cited 15 times.
  393. doi: 10.1016/S0049-3848(97)00143-6
  394. 37.    Öksüzoǧlu, G., Simsek, H., Haznedaroǧlu, I.C., Kirazli, Ş.
  395. Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis
  396. (1997) American Journal of Gastroenterology, 92 (2), pp. 303-306. Cited 16 times.
  397. 38.    Kobayashi, M., Wada, H., Wakita, Y., Shimura, M., Nakase, T., Hiyoyama, K., Nagaya, S., (...), Shiku, H.
  398. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura
  399. (1995) Thrombosis and Haemostasis, 73 (1), pp. 10-14. Cited 37 times.
  400. 39.    Goodwin, C.A., Melissari, E., Kakkar, V.V., Scully, M.F.
  401. Plasma levels of tissue factor pathway inhibitor in thrombophilic patients
  402. (1993) Thrombosis Research, 72 (4), pp. 363-366. Cited 8 times.
  403. doi: 10.1016/0049-3848(93)90147-G
  404. 40.    Llobet, D., Falkon, L., Mateo, J., Vallve, C., Martinez, E., Fontcuberta, J., Borrell, M.
  405. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia.
  406. (1995) Thrombosis Research, 80 (5), pp. 413-418. Cited 15 times.
  407. doi: 10.1016/0049-3848(95)00193-U
  408. 41.    Lindahl, A.K., Jacobsen, P.B., Sandset, P.M., Abildgaard, U.
  409. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients.
  410. (1991) Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis, 2 (6), pp. 713-721. Cited 59 times.
  411. 42.    Wildgoose, P.S., Valentin, S., Nordfang, O.
  412. Evidence that the C-terminus of tissue factor pathwway inhibitor (TFPI) is essential for its interaction with lipoproteins
  413. (1991) Thromb Haemost, 65, p. 768. Cited 2 times.
  414. 43.    Valentin, S., Nordfang, O., Bregengard, C., Wildgoose, P.
  415. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins
  416. (1993) Blood Coagulation and Fibrinolysis, 4 (5), pp. 713-720. Cited 43 times.
  417. 44.    Sandset, P.M., Abildgaard, U., Larsen, M.L.
  418. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
  419. (1988) Thrombosis Research, 50 (6), pp. 803-813. Cited 223 times.
  420. 45.    Hoppensteadt, D.A., Walenga, J.M., Fasanella, A., Jeske, W., Farced, J.
  421. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin
  422. (1995) Thrombosis Research, 77 (2), pp. 175-185. Cited 46 times.
  423. doi: 10.1016/0049-3848(95)91623-S
  424. 46.    Lindahl, A.K., Sandset, P.M., Abildgaard, U.
  425. Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction
  426. (1990) Haemostasis, 20 (5), pp. 253-262. Cited 20 times.
  427. 47.    Ostergaard, P., Nordfang, O., Petersen, L.C., Valentin, S., Kristensen, H.
  428. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations
  429. (1993) Haemostasis, 23 (SUPPL. 1), pp. 107-111. Cited 15 times.
  430. 48.    Hoppensteadt, D.A., Fasanella, A., Fareed, J.
  431. Effect of protamine on heparin releasable TFPI antigen levels in normal volunteers
  432. (1995) Thrombosis Research, 79 (3), pp. 325-330. Cited 2 times.
  433. doi: 10.1016/0049-3848(95)00119-C
  434. 49.    Bara, L., Bloch, M.F., Zitoun, D., Samama, M., Collignon, F., Frydman, A., Uzan, A., (...), Bouthier, J.
  435. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor
  436. (1993) Thrombosis Research, 69 (5), pp. 443-452. Cited 46 times.
  437. doi: 10.1016/0049-3848(93)90233-E
  438. 50.    Ariens, R.A.S., Faioni, E.M., Mannucci, P.M.
  439. Repeated release of the tissue factor pathway inhibitor [3]
  440. (1994) Thrombosis and Haemostasis, 72 (2), pp. 327-328. Cited 11 times.
  441. 51.    Abildgaard, U.
  442. Heparin/low molecular weight heparin and tissue factor pathway inhibitor
  443. (1993) Haemostasis, 23 (SUPPL. 1), pp. 103-106. Cited 37 times.
  444. 52.    Hansen, J.-B., Sandset, P.M., Huseby, K.R., Huseby, N.-E., Bendz, B., Østergaard, P., Nordøy, A.
  445. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action
  446. (1998) British Journal of Haematology, 101 (4), pp. 638-646. Cited 38 times.
  447. doi: 10.1046/j.1365-2141.1998.00770.x
  448. 53.    Kaiser, B., Hoppensteadt, D.A., Jeske, W., Wun, T.C., Fareed, J.
  449. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitromodulatory action of glycosaminoglycans
  450. (1994) Thrombosis Research, 75 (6), pp. 609-616. Cited 16 times.
  451. doi: 10.1016/0049-3848(94)90173-2
  452. 54.    Wun, T.-C.
  453. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides
  454. (1992) Blood, 79 (2), pp. 430-438. Cited 26 times.
  455. 55.    Wesselschmidt, R., Likert, K., Girard, T., Wun, T.-C., Broze Jr., G.J.
  456. Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa
  457. (1992) Blood, 79 (8), pp. 2004-2010. Cited 79 times.
  458. 56.    Kijowski, R., Hoppensteadt, D., Walenga, J., Borris, L., Lassen, M.R., Fareed, J.
  459. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin
  460. (1994) Thrombosis Research, 74 (1), pp. 53-64. Cited 13 times.
  461. doi: 10.1016/0049-3848(94)90035-3
  462.  
  463. 57.    Erhardtsen, E., Madsen, M.T., Ezban, M., Hedner, U., Diness, V., Glazer, S., Nordfang, O.
  464. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced hemophilia A
  465. (1993) Thromb Haemost, 69, p. 556. Cited 5 times.
  466.  
  467. 58.    Holst, J., Lindblad, B., Bergqvist, D., Nordfang, O., Ostergaard, P.B., Petersen, J.G.L., Nielsen, G., (...), Hedner, U.
  468. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI) in experimental venous thrombosis: A comparison with low molecular weight heparin
  469. (1994) Thrombosis and Haemostasis, 71 (2), pp. 214-219. Cited 36 times.
  470. 59.    Hamamoto, T., Yamamoto, M., Nordfang, O., Petersen, J.G.L., Foster, D.C., Kisiel, W.
  471. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces
  472. (1993) Journal of Biological Chemistry, 268 (12), pp. 8704-8710. Cited 41 times.
  473. 60.    Holst, J., Lindblad, B., Wedeberg, E., Bergqvist, D., Nordfang, O., Ostergaard, P.B., Hedner, U.
  474. Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
  475. (1993) Thrombosis Research, 72 (5), pp. 467-470. Cited 11 times.
  476. doi: 10.1016/0049-3848(93)90248-M
  477. 61.    Girard, T.J., MacPhail, L.A., Likert, K.M., Novotny, W.F., Miletich, J.P., Broze Jr., G.J.
  478. Inhibition of a factor VIIa-tissue factor coagulation activity by a hybrid protein
  479. (1990) Science, 248 (4961), pp. 1421-1424. Cited 38 times.
  480. 62.    Day, K.C., Welsch, D.J.
  481. Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor XA
  482. (1992) Thrombosis Research, 68 (4-5), pp. 369-381. Cited 6 times.
  483. doi: 10.1016/0049-3848(92)90095-R
  484. 63.    Eisenberg, P.R., Siegel, J.E., Abendschein, D.R., Miletich, J.P.
  485. Importance of factor Xa in determining the procoagulant activity of whole- blood clots
  486. (1993) Journal of Clinical Investigation, 91 (5), pp. 1877-1883. Cited 108 times.
  487. 64.    Lindhout, T., Franssen, J., Willems, G.
  488. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor
  489. (1995) Thrombosis and Haemostasis, 74 (3), pp. 910-915. Cited 40 times.
  490. 65.    Broze Jr., G.J.
  491. Tissue factor pathway inhibitor
  492. (1995) Thrombosis and Haemostasis, 74 (1), pp. 90-93. Cited 206 times.
  493. 66.    Enjoyji, K., Miyata, T., Kamikubo, Y., Kato, J.
  494. Effect of heparin on the inhibition of FXa by tissue factor pathway inhibitor: A segment, Gly212- Phe 243, of the third kunitz domain is a heparin binding site
  495. (1995) Biochemistry, 34, pp. 5727-5735.
  496. 67.    Bajaj, M.S., Bajaj, S.P.
  497. Tissue factor pathway inhibitor: Potential therapeutic applications
  498. (1997) Thrombosis and Haemostasis, 78 (1), pp. 471-477. Cited 94 times.
  499. 68.    Kamikubo, Y.-I., Hamuro, T., Matsuda, J.-I., Kamei, S., Jyu-Ri, K., Miyamoto, S., Funatsu, A., (...), Kato, H.
  500. The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (H-RTFPI) in rabbits: A complex formation of H- RTFPI with factor Xa promotes a clearance rate of H-RTFPI
  501. (1996) Thrombosis Research, 83 (2), pp. 161-173. Cited 9 times.
  502. doi: 10.1016/0049-3848(96)00117-X
  503. 69.    Holst, J., Lindblad, B., Westerlund, G., Bregengaard, C., Ezban, M., ØStergaard, P.B., Nordfang, O., (...), Hedner, U.
  504. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor
  505. (1996) Thrombosis Research, 81 (4), pp. 461-470. Cited 6 times.
  506. doi: 10.1016/0049-3848(96)00018-7
  507.  70.    Day, K.C., Hoffman, L.C., Palmier, M.O., Kretzmer, K.K., Huang, M.D., Pyla, E.Y., Spokas, E., (...), Wun, T.-C.
  508. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit
  509. (1990) Blood, 76 (8), pp. 1538-1545. Cited 40 times.
  510. 71.    Bregengard, C., Nordfang, O., Wildgoose, P., Svendsen, O., Hedner, U., Diness, V.
  511. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits
  512. (1993) Blood Coagulation and Fibrinolysis, 4 (5), pp. 699-706. Cited 49 times.
  513. 72.    Camerota, A.J., Creasey, A.A., Patla, V., Larkin, V.A., Fink, M.P.
  514. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
  515. (1998) Journal of Infectious Diseases, 177 (3), pp. 668-676. Cited 63 times.
  516.  73.    Girard, T.J.
  517. Tissue factor pathway inhibitor
  518. (1997) Novel Therapeutic Agents in Thrombosis and Thrombolysis, pp. 225-260. Cited 8 times.
  519. Sasahara A, Loscalzo J, eds. New York: Marcel Dekker
  520. Oostryck, R.; School of Biomedical Sciences, Curtin University of Technology, GPO Box U 1987, Perth, WA 6845, Australia; email:r.oostryck@info.curtin.edu.au 
  521. © Copyright 2006 Elsevier B.V., All rights reserved
  522.  
  523.  
  524.  
  525.  
  526.  
  527. 57.    Erhardtsen, E., Madsen, M.T., Ezban, M., Hedner, U., Diness, V., Glazer, S., Nordfang, O.
  528. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced hemophilia A
  529. (1993) Thromb Haemost, 69, p. 556. Cited 5 times.
  530.  
  531. 58.    Holst, J., Lindblad, B., Bergqvist, D., Nordfang, O., Ostergaard, P.B., Petersen, J.G.L., Nielsen, G., (...), Hedner, U.
  532. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI) in experimental venous thrombosis: A comparison with low molecular weight heparin
  533. (1994) Thrombosis and Haemostasis, 71 (2), pp. 214-219. Cited 36 times.
  534. 59.    Hamamoto, T., Yamamoto, M., Nordfang, O., Petersen, J.G.L., Foster, D.C., Kisiel, W.
  535. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces
  536. (1993) Journal of Biological Chemistry, 268 (12), pp. 8704-8710. Cited 41 times.
  537. 60.    Holst, J., Lindblad, B., Wedeberg, E., Bergqvist, D., Nordfang, O., Ostergaard, P.B., Hedner, U.
  538. Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
  539. (1993) Thrombosis Research, 72 (5), pp. 467-470. Cited 11 times.
  540. doi: 10.1016/0049-3848(93)90248-M
  541. 61.    Girard, T.J., MacPhail, L.A., Likert, K.M., Novotny, W.F., Miletich, J.P., Broze Jr., G.J.
  542. Inhibition of a factor VIIa-tissue factor coagulation activity by a hybrid protein
  543. (1990) Science, 248 (4961), pp. 1421-1424. Cited 38 times.
  544. 62.    Day, K.C., Welsch, D.J.
  545. Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor XA
  546. (1992) Thrombosis Research, 68 (4-5), pp. 369-381. Cited 6 times.
  547. doi: 10.1016/0049-3848(92)90095-R
  548. 63.    Eisenberg, P.R., Siegel, J.E., Abendschein, D.R., Miletich, J.P.
  549. Importance of factor Xa in determining the procoagulant activity of whole- blood clots
  550. (1993) Journal of Clinical Investigation, 91 (5), pp. 1877-1883. Cited 108 times.
  551. 64.    Lindhout, T., Franssen, J., Willems, G.
  552. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor
  553. (1995) Thrombosis and Haemostasis, 74 (3), pp. 910-915. Cited 40 times.
  554. 65.    Broze Jr., G.J.
  555. Tissue factor pathway inhibitor
  556. (1995) Thrombosis and Haemostasis, 74 (1), pp. 90-93. Cited 206 times.
  557. 66.    Enjoyji, K., Miyata, T., Kamikubo, Y., Kato, J.
  558. Effect of heparin on the inhibition of FXa by tissue factor pathway inhibitor: A segment, Gly212- Phe 243, of the third kunitz domain is a heparin binding site
  559. (1995) Biochemistry, 34, pp. 5727-5735.
  560. 67.    Bajaj, M.S., Bajaj, S.P.
  561. Tissue factor pathway inhibitor: Potential therapeutic applications
  562. (1997) Thrombosis and Haemostasis, 78 (1), pp. 471-477. Cited 94 times.
  563. 68.    Kamikubo, Y.-I., Hamuro, T., Matsuda, J.-I., Kamei, S., Jyu-Ri, K., Miyamoto, S., Funatsu, A., (...), Kato, H.
  564. The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (H-RTFPI) in rabbits: A complex formation of H- RTFPI with factor Xa promotes a clearance rate of H-RTFPI
  565. (1996) Thrombosis Research, 83 (2), pp. 161-173. Cited 9 times.
  566. doi: 10.1016/0049-3848(96)00117-X
  567.  
  568.       
  569.  
  570. 69.    Holst, J., Lindblad, B., Westerlund, G., Bregengaard, C., Ezban, M., ØStergaard, P.B., Nordfang, O., (...), Hedner, U.
  571. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor
  572. (1996) Thrombosis Research, 81 (4), pp. 461-470. Cited 6 times.
  573. doi: 10.1016/0049-3848(96)00018-7
  574.  70.    Day, K.C., Hoffman, L.C., Palmier, M.O., Kretzmer, K.K., Huang, M.D., Pyla, E.Y., Spokas, E., (...), Wun, T.-C.
  575. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit
  576. (1990) Blood, 76 (8), pp. 1538-1545. Cited 40 times.
  577. 71.    Bregengard, C., Nordfang, O., Wildgoose, P., Svendsen, O., Hedner, U., Diness, V.
  578. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits
  579. (1993) Blood Coagulation and Fibrinolysis, 4 (5), pp. 699-706. Cited 49 times.
  580. 72.    Camerota, A.J., Creasey, A.A., Patla, V., Larkin, V.A., Fink, M.P.
  581. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
  582. (1998) Journal of Infectious Diseases, 177 (3), pp. 668-676. Cited 63 times.
  583.  73.    Girard, T.J.
  584. Tissue factor pathway inhibitor
  585. (1997) Novel Therapeutic Agents in Thrombosis and Thrombolysis, pp. 225-260. Cited 8 times.
  586. Sasahara A, Loscalzo J, eds. New York: Marcel Dekker
  587. Oostryck, R.; School of Biomedical Sciences, Curtin University of Technology, GPO Box U 1987, Perth, WA 6845, Australia; email:r.oostryck@info.curtin.edu.au 
  588. © Copyright 2006 Elsevier B.V., All rights reserved
  589.  
  590.  
  591.   
  592.  
  593.  
  594.  
  595.  
  596.  
  597.   
  598. " name="eprints.referencetext" />
  599. <meta content="Adams, M.J. and Oostryck, R. (2000) Tissue factor pathway inhibitor: Regulator of the tissue factor pathway of coagulation and a future antithrombotic agent? Australian Journal of Medical Science, 21 (1). pp. 2-9. ISSN 1038-1643" name="eprints.citation" />
  600. <meta content="http://eprints.utas.edu.au/2357/1/Tissue_Factor.pdf" name="eprints.document_url" />
  601. <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
  602. <meta content="Tissue factor pathway inhibitor: Regulator of the tissue factor pathway of coagulation and a future antithrombotic agent?" name="DC.title" />
  603. <meta content="Adams, M.J." name="DC.creator" />
  604. <meta content="Oostryck, R." name="DC.creator" />
  605. <meta content="320000 Medical and Health Sciences" name="DC.subject" />
  606. <meta content="Tissue factor pathway inhibitor (TFPI) is a recently 'rediscovered' inhibitor of tissue factor mediated coagulation that has a central role in the modern hypothesis of coagulation. The regulatory role of this inhibitor has redefined the classical extrinsic and intrinsic pathways of coagulation and helps to explain why haemophiliacs bleed. Comprehensive investigations have been performed during the last 15 years to elucidate the structure, distribution, function and physiological characteristics of TFPI. More recent work has focused on the therapeutic potential of TFPI as an antithrombotic agent. Augmentation of TFPI levels may provide treatment for thrombotic disorders such as disseminated intravascular coagulation and deep vein thrombosis. Full length and truncated forms of TFPI molecules are also being considered as antithrombotic agents. These have been used in a number of animal models with initial results demonstrating the alleviation of thrombotic tendencies. Trials are currently ongoing." name="DC.description" />
  607. <meta content="2000" name="DC.date" />
  608. <meta content="Article" name="DC.type" />
  609. <meta content="PeerReviewed" name="DC.type" />
  610. <meta content="application/pdf" name="DC.format" />
  611. <meta content="http://eprints.utas.edu.au/2357/1/Tissue_Factor.pdf" name="DC.identifier" />
  612. <meta content="http://www.aims.org.au/c/" name="DC.relation" />
  613. <meta content="Adams, M.J. and Oostryck, R. (2000) Tissue factor pathway inhibitor: Regulator of the tissue factor pathway of coagulation and a future antithrombotic agent? Australian Journal of Medical Science, 21 (1). pp. 2-9. ISSN 1038-1643" name="DC.identifier" />
  614. <meta content="http://eprints.utas.edu.au/2357/" name="DC.relation" />
  615. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/BibTeX/epprod-eprint-2357.bib" title="BibTeX" type="text/plain" />
  616. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/ContextObject/epprod-eprint-2357.xml" title="OpenURL ContextObject" type="text/xml" />
  617. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/ContextObject::Dissertation/epprod-eprint-2357.xml" title="OpenURL Dissertation" type="text/xml" />
  618. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/ContextObject::Journal/epprod-eprint-2357.xml" title="OpenURL Journal" type="text/xml" />
  619. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/DC/epprod-eprint-2357.txt" title="Dublin Core" type="text/plain" />
  620. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/DIDL/epprod-eprint-2357.xml" title="DIDL" type="text/xml" />
  621. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/EndNote/epprod-eprint-2357.enw" title="EndNote" type="text/plain" />
  622. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/HTML/epprod-eprint-2357.html" title="HTML Citation" type="text/html; charset=utf-8" />
  623. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/METS/epprod-eprint-2357.xml" title="METS" type="text/xml" />
  624. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/MODS/epprod-eprint-2357.xml" title="MODS" type="text/xml" />
  625. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/RIS/epprod-eprint-2357.ris" title="Reference Manager" type="text/plain" />
  626. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/Refer/epprod-eprint-2357.refer" title="Refer" type="text/plain" />
  627. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/Simple/epprod-eprint-2357text" title="Simple Metadata" type="text/plain" />
  628. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/Text/epprod-eprint-2357.txt" title="ASCII Citation" type="text/plain; charset=utf-8" />
  629. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2357/XML/epprod-eprint-2357.xml" title="EP3 XML" type="text/xml" />
  630.  
  631.   </head>
  632.   <body bgcolor="#ffffff" text="#000000" onLoad="loadRoutine(); MM_preloadImages('images/eprints/ePrints_banner_r5_c5_f2.gif','images/eprints/ePrints_banner_r5_c7_f2.gif','images/eprints/ePrints_banner_r5_c8_f2.gif','images/eprints/ePrints_banner_r5_c9_f2.gif','images/eprints/ePrints_banner_r5_c10_f2.gif','images/eprints/ePrints_banner_r5_c11_f2.gif','images/eprints/ePrints_banner_r6_c4_f2.gif')">
  633.     
  634.     <div class="ep_noprint"><noscript><style type="text/css">@import url(http://eprints.utas.edu.au/style/nojs.css);</style></noscript></div>
  635.  
  636.  
  637.  
  638.  
  639. <table width="795" border="0" cellspacing="0" cellpadding="0">
  640.   <tr>
  641.     <td><script language="JavaScript1.2">mmLoadMenus();</script>
  642.       <table border="0" cellpadding="0" cellspacing="0" width="795">
  643.         <!-- fwtable fwsrc="eprints_banner_final2.png" fwbase="ePrints_banner.gif" fwstyle="Dreamweaver" fwdocid = "1249563342" fwnested="0" -->
  644.         <tr>
  645.           <td><img src="/images/eprints/spacer.gif" width="32" height="1" border="0" alt="" /></td>
  646.           <td><img src="/images/eprints/spacer.gif" width="104" height="1" border="0" alt="" /></td>
  647.           <td><img src="/images/eprints/spacer.gif" width="44" height="1" border="0" alt="" /></td>
  648.           <td><img src="/images/eprints/spacer.gif" width="105" height="1" border="0" alt="" /></td>
  649.           <td><img src="/images/eprints/spacer.gif" width="41" height="1" border="0" alt="" /></td>
  650.           <td><img src="/images/eprints/spacer.gif" width="16" height="1" border="0" alt="" /></td>
  651.           <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  652.           <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  653.           <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  654.           <td><img src="/images/eprints/spacer.gif" width="82" height="1" border="0" alt="" /></td>
  655.           <td><img src="/images/eprints/spacer.gif" width="69" height="1" border="0" alt="" /></td>
  656.           <td><img src="/images/eprints/spacer.gif" width="98" height="1" border="0" alt="" /></td>
  657.           <td><img src="/images/eprints/spacer.gif" width="1" height="1" border="0" alt="" /></td>
  658.         </tr>
  659.         <tr>
  660.           <td colspan="12"><img name="ePrints_banner_r1_c1" src="/images/eprints/ePrints_banner_r1_c1.gif" width="795" height="10" border="0" alt="" /></td>
  661.           <td><img src="/images/eprints/spacer.gif" width="1" height="10" border="0" alt="" /></td>
  662.         </tr>
  663.         <tr>
  664.           <td rowspan="6"><img name="ePrints_banner_r2_c1" src="/images/eprints/ePrints_banner_r2_c1.gif" width="32" height="118" border="0" alt="" /></td>
  665.           <td rowspan="5"><a href="http://www.utas.edu.au/"><img name="ePrints_banner_r2_c2" src="/images/eprints/ePrints_banner_r2_c2.gif" width="104" height="103" border="0" alt="" /></a></td>
  666.           <td colspan="10"><img name="ePrints_banner_r2_c3" src="/images/eprints/ePrints_banner_r2_c3.gif" width="659" height="41" border="0" alt="" /></td>
  667.           <td><img src="/images/eprints/spacer.gif" width="1" height="41" border="0" alt="" /></td>
  668.         </tr>
  669.         <tr>
  670.           <td colspan="3"><a href="http://eprints.utas.edu.au/"><img name="ePrints_banner_r3_c3" src="/images/eprints/ePrints_banner_r3_c3.gif" width="190" height="31" border="0" alt="" /></a></td>
  671.           <td rowspan="2" colspan="7"><img name="ePrints_banner_r3_c6" src="/images/eprints/ePrints_banner_r3_c6.gif" width="469" height="37" border="0" alt="" /></td>
  672.           <td><img src="/images/eprints/spacer.gif" width="1" height="31" border="0" alt="" /></td>
  673.         </tr>
  674.         <tr>
  675.           <td colspan="3"><img name="ePrints_banner_r4_c3" src="/images/eprints/ePrints_banner_r4_c3.gif" width="190" height="6" border="0" alt="" /></td>
  676.           <td><img src="/images/eprints/spacer.gif" width="1" height="6" border="0" alt="" /></td>
  677.         </tr>
  678.         <tr>
  679.           <td colspan="2"><img name="ePrints_banner_r5_c3" src="/images/eprints/ePrints_banner_r5_c3.gif" width="149" height="1" border="0" alt="" /></td>
  680.           <td rowspan="2" colspan="2"><a href="/information.html" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821132634_0,0,25,null,'ePrints_banner_r5_c5');MM_swapImage('ePrints_banner_r5_c5','','/images/eprints/ePrints_banner_r5_c5_f2.gif',1);"><img name="ePrints_banner_r5_c5" src="/images/eprints/ePrints_banner_r5_c5.gif" width="57" height="25" border="0" alt="About" /></a></td>
  681.           <td rowspan="2"><a href="/view/" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133021_1,0,25,null,'ePrints_banner_r5_c7');MM_swapImage('ePrints_banner_r5_c7','','/images/eprints/ePrints_banner_r5_c7_f2.gif',1);"><img name="ePrints_banner_r5_c7" src="/images/eprints/ePrints_banner_r5_c7.gif" width="68" height="25" border="0" alt="Browse" /></a></td>
  682.           <td rowspan="2"><a href="/perl/search/simple" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133201_2,0,25,null,'ePrints_banner_r5_c8');MM_swapImage('ePrints_banner_r5_c8','','/images/eprints/ePrints_banner_r5_c8_f2.gif',1);"><img name="ePrints_banner_r5_c8" src="/images/eprints/ePrints_banner_r5_c8.gif" width="68" height="25" border="0" alt="Search" /></a></td>
  683.           <td rowspan="2"><a href="/perl/register" onMouseOut="MM_swapImgRestore();MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_1018171924_3,0,25,null,'ePrints_banner_r5_c9');MM_swapImage('ePrints_banner_r5_c9','','/images/eprints/ePrints_banner_r5_c9_f2.gif',1);"><img name="ePrints_banner_r5_c9" src="/images/eprints/ePrints_banner_r5_c9.gif" width="68" height="25" border="0" alt="register" /></a></td>
  684.           <td rowspan="2"><a href="/perl/users/home" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133422_4,0,25,null,'ePrints_banner_r5_c10');MM_swapImage('ePrints_banner_r5_c10','','/images/eprints/ePrints_banner_r5_c10_f2.gif',1);"><img name="ePrints_banner_r5_c10" src="/images/eprints/ePrints_banner_r5_c10.gif" width="82" height="25" border="0" alt="user area" /></a></td>
  685.           <td rowspan="2"><a href="/help/" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133514_5,0,25,null,'ePrints_banner_r5_c11');MM_swapImage('ePrints_banner_r5_c11','','/images/eprints/ePrints_banner_r5_c11_f2.gif',1);"><img name="ePrints_banner_r5_c11" src="/images/eprints/ePrints_banner_r5_c11.gif" width="69" height="25" border="0" alt="Help" /></a></td>
  686.           <td rowspan="3" colspan="4"><img name="ePrints_banner_r5_c12" src="/images/eprints/ePrints_banner_r5_c12.gif" width="98" height="40" border="0" alt="" /></td>
  687.           <td><img src="/images/eprints/spacer.gif" width="1" height="1" border="0" alt="" /></td>
  688.         </tr>
  689.         <tr>
  690.           <td rowspan="2"><img name="ePrints_banner_r6_c3" src="/images/eprints/ePrints_banner_r6_c3.gif" width="44" height="39" border="0" alt="ePrints home" /></td>
  691.           <td><a href="/" onMouseOut="MM_swapImgRestore()" onMouseOver="MM_swapImage('ePrints_banner_r6_c4','','/images/eprints/ePrints_banner_r6_c4_f2.gif',1);"><img name="ePrints_banner_r6_c4" src="/images/eprints/ePrints_banner_r6_c4.gif" width="105" height="24" border="0" alt="ePrints home" /></a></td>
  692.           <td><img src="/images/eprints/spacer.gif" width="1" height="24" border="0" alt="" /></td>
  693.         </tr>
  694.         <tr>
  695.           <td><img name="ePrints_banner_r7_c2" src="/images/eprints/ePrints_banner_r7_c2.gif" width="104" height="15" border="0" alt="" /></td>
  696.           <td colspan="8"><img name="ePrints_banner_r7_c4" src="/images/eprints/ePrints_banner_r7_c4.gif" width="517" height="15" border="0" alt="" /></td>
  697.           <td><img src="/images/eprints/spacer.gif" width="1" height="15" border="0" alt="" /></td>
  698.         </tr>
  699.       </table></td>
  700.   </tr>
  701.     <tr><td><table width="100%" style="font-size: 90%; border: solid 1px #ccc; padding: 3px"><tr>
  702.       <td align="left"><a href="http://eprints.utas.edu.au/cgi/users/home">Login</a> | <a href="http://eprints.utas.edu.au/cgi/register">Create Account</a></td>
  703.       <td align="right" style="white-space: nowrap">
  704.         <form method="get" accept-charset="utf-8" action="http://eprints.utas.edu.au/cgi/search" style="display:inline">
  705.           <input class="ep_tm_searchbarbox" size="20" type="text" name="q" />
  706.           <input class="ep_tm_searchbarbutton" value="Search" type="submit" name="_action_search" />
  707.           <input type="hidden" name="_order" value="bytitle" />
  708.           <input type="hidden" name="basic_srchtype" value="ALL" />
  709.           <input type="hidden" name="_satisfyall" value="ALL" />
  710.         </form>
  711.       </td>
  712.     </tr></table></td></tr>
  713.   <tr>
  714.     <td class="toplinks"><!-- InstanceBeginEditable name="content" -->
  715.  
  716.  
  717. <div align="center">
  718.   
  719.   <table width="720" class="ep_tm_main"><tr><td align="left">
  720.     <h1 class="ep_tm_pagetitle">Tissue factor pathway inhibitor: Regulator of the tissue factor pathway of coagulation and a future antithrombotic agent?</h1>
  721.     <p style="margin-bottom: 1em" class="not_ep_block"><span class="person_name">Adams, M.J.</span> and <span class="person_name">Oostryck, R.</span> (2000) <xhtml:em>Tissue factor pathway inhibitor: Regulator of the tissue factor pathway of coagulation and a future antithrombotic agent?</xhtml:em> Australian Journal of Medical Science, 21 (1). pp. 2-9. ISSN 1038-1643</p><p style="margin-bottom: 1em" class="not_ep_block"></p><table style="margin-bottom: 1em" class="not_ep_block"><tr><td valign="top" style="text-align:center"><a href="http://eprints.utas.edu.au/2357/1/Tissue_Factor.pdf"><img alt="[img]" src="http://eprints.utas.edu.au/style/images/fileicons/application_pdf.png" class="ep_doc_icon" border="0" /></a></td><td valign="top"><a href="http://eprints.utas.edu.au/2357/1/Tissue_Factor.pdf"><span class="ep_document_citation">PDF</span></a> - Full text restricted - Requires a PDF viewer<br />2062Kb</td><td><form method="get" accept-charset="utf-8" action="http://eprints.utas.edu.au/cgi/request_doc"><input accept-charset="utf-8" value="3015" name="docid" type="hidden" /><div class=""><input value="Request a copy" name="_action_null" class="ep_form_action_button" onclick="return EPJS_button_pushed( '_action_null' )" type="submit" /> </div></form></td></tr></table><p style="margin-bottom: 1em" class="not_ep_block">Official URL: <a href="http://www.aims.org.au/c/">http://www.aims.org.au/c/</a></p><div class="not_ep_block"><h2>Abstract</h2><p style="padding-bottom: 16px; text-align: left; margin: 1em auto 0em auto">Tissue factor pathway inhibitor (TFPI) is a recently 'rediscovered' inhibitor of tissue factor mediated coagulation that has a central role in the modern hypothesis of coagulation. The regulatory role of this inhibitor has redefined the classical extrinsic and intrinsic pathways of coagulation and helps to explain why haemophiliacs bleed. Comprehensive investigations have been performed during the last 15 years to elucidate the structure, distribution, function and physiological characteristics of TFPI. More recent work has focused on the therapeutic potential of TFPI as an antithrombotic agent. Augmentation of TFPI levels may provide treatment for thrombotic disorders such as disseminated intravascular coagulation and deep vein thrombosis. Full length and truncated forms of TFPI molecules are also being considered as antithrombotic agents. These have been used in a number of animal models with initial results demonstrating the alleviation of thrombotic tendencies. Trials are currently ongoing.</p></div><table style="margin-bottom: 1em" cellpadding="3" class="not_ep_block" border="0"><tr><th valign="top" class="ep_row">Item Type:</th><td valign="top" class="ep_row">Article</td></tr><tr><th valign="top" class="ep_row">Keywords:</th><td valign="top" class="ep_row">Antithrombotic agent; Coagulation; Thrombosis; Tissue factor; Tissue factor pathway inhibitor&#13;
  722. &#13;
  723. &#13;
  724. &#13;
  725. </td></tr><tr><th valign="top" class="ep_row">Subjects:</th><td valign="top" class="ep_row"><a href="http://eprints.utas.edu.au/view/subjects/320000.html">320000 Medical and Health Sciences</a></td></tr><tr><th valign="top" class="ep_row">ID Code:</th><td valign="top" class="ep_row">2357</td></tr><tr><th valign="top" class="ep_row">Deposited By:</th><td valign="top" class="ep_row"><span class="ep_name_citation"><span class="person_name">Scholarly Publications Librarian</span></span></td></tr><tr><th valign="top" class="ep_row">Deposited On:</th><td valign="top" class="ep_row">02 Nov 2007 11:22</td></tr><tr><th valign="top" class="ep_row">Last Modified:</th><td valign="top" class="ep_row">09 Jan 2008 02:30</td></tr><tr><th valign="top" class="ep_row">ePrint Statistics:</th><td valign="top" class="ep_row"><a target="ePrintStats" href="/es/index.php?action=show_detail_eprint;id=2357;">View statistics for this ePrint</a></td></tr></table><p align="right">Repository Staff Only: <a href="http://eprints.utas.edu.au/cgi/users/home?screen=EPrint::View&amp;eprintid=2357">item control page</a></p>
  726.   </td></tr></table>
  727. </div>
  728.  
  729.  
  730.  
  731.     <!-- InstanceEndEditable --></td>
  732.   </tr>
  733.   <tr>
  734.     <td><!-- #BeginLibraryItem "/Library/footer_eprints.lbi" -->
  735.     <table width="795" border="0" align="left" cellpadding="0" class="footer">
  736.   <tr valign="top">
  737. <td colspan="2"><div align="center"><a href="http://www.utas.edu.au">UTAS home</a> | <a href="http://www.utas.edu.au/library/">Library home</a> | <a href="/">ePrints home</a> | <a href="/contact.html">contact</a> | <a href="/information.html">about</a> | <a href="/view/">browse</a> | <a href="/perl/search/simple">search</a> | <a href="/perl/register">register</a> | <a href="/perl/users/home">user area</a> | <a href="/help/">help</a></div><br /></td>
  738. </tr>
  739. <tr><td colspan="2"><p><img src="/images/eprints/footerline.gif" width="100%" height="4" /></p></td></tr>
  740.       <tr valign="top">
  741.         <td width="68%" class="footer">Authorised by the University Librarian<br />
  742. © University of Tasmania ABN 30 764 374 782<br />
  743.       <a href="http://www.utas.edu.au/cricos/">CRICOS Provider Code 00586B</a> | <a href="http://www.utas.edu.au/copyright/copyright_disclaimers.html">Copyright &amp; Disclaimers</a> | <a href="http://www.utas.edu.au/accessibility/index.html">Accessibility</a> | <a href="http://eprints.utas.edu.au/feedback/">Site Feedback</a>  </td>
  744.         <td width="32%"><div align="right">
  745.             <p align="right" class="NoPrint"><a href="http://www.utas.edu.au/"><img src="http://www.utas.edu.au/shared/logos/unioftasstrip.gif" alt="University of Tasmania Home Page" width="260" height="16" border="0" align="right" /></a></p>
  746.             <p align="right" class="NoPrint"><a href="http://www.utas.edu.au/"><br />
  747.             </a></p>
  748.         </div></td>
  749.       </tr>
  750.       <tr valign="top">
  751.         <td><p>  </p></td>
  752.         <td><div align="right"><span class="NoPrint"><a href="http://www.eprints.org/software/"><img src="/images/eprintslogo.gif" alt="ePrints logo" width="77" height="29" border="0" align="bottom" /></a></span></div></td>
  753.       </tr>
  754.     </table>
  755.     <!-- #EndLibraryItem -->
  756.     <div align="center"></div></td>
  757.   </tr>
  758. </table>
  759.  
  760.   </body>
  761. </html>